Ozempic generics are about to enter some of the world’s biggest pharmaceutical markets as Novo Nordisk loses key patent protection for semaglutide in countries including India, China, Brazil, Turkey, South Africa and Canada. The shift could cut the cost of treatment sharply in places where the drug has remained out of reach for most patients, while leaving the USA and Europe on a different timeline.
The Danish drugmaker built a global blockbuster around semaglutide, the active ingredient sold as Ozempic for type 2 diabetes and Wegovy for obesity. But from 21 March, manufacturers in several countries will be able to compete more directly with cheaper versions, opening a new phase in the market for GLP-1 medicines.
Why semaglutide patents matter for access
For years, high prices have limited access to semaglutide outside wealthier markets. In practice, that meant the drug’s medical impact was unevenly distributed: strong demand, high visibility and proven benefits, but restricted availability for large parts of the global population.
That may now begin to change. India and China alone account for hundreds of millions of adults living with diabetes, overweight or obesity. In those markets, the arrival of lower-cost generics could expand treatment well beyond high-income urban patients who were able to pay out of pocket.
Semaglutide belongs to the GLP-1 receptor agonist class, which helps regulate blood sugar and appetite. Initially developed for diabetes care, it later became one of the most discussed treatments for obesity because of its weight-loss effects. Evidence has also strengthened around broader health benefits, including cardiovascular protection for some patients, although it remains a prescription medicine with clear limits and side effects.
India could become the first big semaglutide test case
India is expected to be the first major market where generic semaglutide arrives at scale. Reuters reported that more than 40 Indian drugmakers are preparing over 50 brands, with some launches expected immediately after patent expiry.
That matters because India is both a large pharmaceutical producer and a highly price-sensitive market. Analysts cited by Reuters expect early generic prices to come in at least 50 to 60 percent below Novo Nordisk’s branded products, with monthly costs potentially falling from around 11,000 Indian rupees to 3,000–5,000 rupees (€33–€55), and possibly lower over time.
Several companies had already moved before the patent deadline. Reuters reported in January that Sun Pharma, Zydus Lifesciences and Alkem Laboratories had received regulatory approval to manufacture and sell generic semaglutide in India. Zydus has also signed a co-marketing deal with Lupin, while other Indian manufacturers are preparing rival launches.
If prices fall as expected, India could become the clearest example yet of how off-patent GLP-1 medicines might move from a premium product to a broader public-health treatment.
China and other markets are next in line
The same dynamic is expected in other large markets where patent barriers are ending or weakening. China is especially important because of both its patient base and its manufacturing capacity. Multiple Chinese companies have reportedly been advancing through the regulatory process, and lower-cost competition is expected in the coming months.
Canada is on a slightly different timetable. Patent protection there had already weakened earlier in 2026, but cheaper versions are expected to take longer to reach pharmacies because of regulatory and commercial timing. Brazil, Turkey and South Africa are also among the countries where semaglutide generics are expected to broaden access this year.
Together, these markets represent a large share of the world’s population and a significant part of future demand for obesity and diabetes treatment. That is why the patent cliff matters not only for patients, but also for the structure of the global pharmaceutical market.
Novo Nordisk faces a more competitive phase
For Novo Nordisk, the expiry marks another difficult moment after two years of extraordinary growth followed by mounting competitive pressure. The company turned Ozempic and Wegovy into some of the most commercially successful medicines in the world, helping make Novo briefly Europe’s most valuable listed company in 2024.
That position has become harder to defend. Eli Lilly’s rival medicines, sold as Mounjaro for diabetes and Zepbound for obesity, have already taken market share in several countries. At the same time, lower-cost copies and future generics are forcing Novo Nordisk to defend prices more aggressively.
According to reporting by The New York Times and Reuters, Novo Nordisk has challenged generics in court in some countries and has also cut prices in markets such as India and China ahead of competition. The company may still retain an advantage among patients and doctors who trust the originator brand, but the monopoly phase is ending in a substantial part of the world.
Why Europe and the USA will have to wait
The picture is different in Europe and the USA, where semaglutide is not expected to face full generic competition until the early 2030s. The main reason is not the basic patent term alone, but the additional regulatory protections that extend market exclusivity for innovative drugmakers.
That means patients in the European Union and the USA are likely to keep paying much higher prices for longer than patients in some emerging markets. It also creates an unusual reversal: in this case, some middle-income countries may gain access to cheaper Ozempic generics years before richer healthcare systems do.
For European readers, and especially for a Nordic audience, this is a notable turning point. A Danish pharmaceutical champion remains central to one of the decade’s biggest medical stories, but the next phase may be defined less by exclusive innovation and more by the global politics of patents, pricing and access.
